人福醫藥(600079.SH)及下屬控股子公司沒有鹽酸阿比多爾、達蘆那韋製劑生產批件
格隆匯2月6日丨人福醫藥(600079.SH)公佈,公司股票於2020年2月4日、2020年2月5日、2020年2月6日連續三個交易日漲幅累計達25.53%。
公司關注到部分媒體報道子公司湖北生物醫藥產業技術研究院有限公司(“醫藥研究院”,公司持有其50.24%的股權)持有關於“阿比朵爾片劑”的專利。醫藥研究院僅持有關於鹽酸阿比多爾(Arbidol,或譯為阿比朵爾)製備相關的專利,但截至目前尚未開展生物等效性實驗也未生產,該研發項目不會對公司2020年度經營業績產生重大影響。經自查,公司及下屬控股子公司沒有鹽酸阿比多爾、達蘆那韋製劑的生產批件,也未開展達蘆那韋製劑的研發項目。
公司關注到部分媒體報道子公司湖北人福醫藥集團有限公司(“人福湖北”)根據湖北省新型冠狀病毒感染肺炎疫情防控指揮部的委託進行防控應急物資的採購配送。該事項不會對公司2020年度經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.